Journal
WORLD JOURNAL OF SURGICAL ONCOLOGY
Volume 10, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1477-7819-10-274
Keywords
FISH; Gastric cancer; HER-2/neu; IHC; Prognosis
Funding
- National Natural Science Foundation of China [81071667]
- Science and technology commission of Shanghai Municipality [09DZ1950100]
Ask authors/readers for more resources
Background: HER-2/neu-targeted therapy has been successfully used in advanced gastric cancer, but the role of HER-2/neu in the prognosis of gastric cancer is not yet clear. In this study, we investigated the correlation between HER-2/neu expression and amplification as well as their association with clinic outcomes in patients with curatively resected gastric cancer. Methods: We constructed tissue microarray blocks containing >70% of gastric cancer tissue and matched adjacent normal gastric tissue for 227 patients. Expression of the HER-2/neu protein in these specimens was analyzed using immunohistochemical staining. Amplification of HER-2/neu was also analyzed for the same samples using fluorescence in situ hybridization. Data on clinicopathological features and relevant prognostic factors in these patients were analyzed. Results: Of the 227 gastric cancer samples, 11.89% were positive for HER-2/neu overexpression/amplification under the new scoring system. HER-2/neu overexpression/amplification was closely correlated to the Lauren type, degree of differentiation, tumor size and lymph node metastasis. HER-2/neu overexpression/amplification predicted poor survival in univariate analysis but not in a Cox proportional hazards model. Conclusion: HER-2/neu overexpression/amplification was not an independent predictor for survival in patients with curatively resected gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available